EZH2 and cancer: In contrast, the specific catalytic inhibitors of EZH2, such as GSK126 or GSK343, though potent in killing some hematological malignant cells such as the diffuse large B-cell lymphoma (DLBCL) that carry EZH2 activating mutations [10, 39], do not seem to be effective in cancer cells overexpressing a wild type EZH2 and only have a modest effect, if any, on EZH2 target gene expression [9, 40].